United States Patent 8,506,929 (Claim Scope and IP Landscape): Amyloid Imaging Compounds Featuring —F/—¹⁸F Substitution
United States Patent 8,506,929 is directed to (i) specific substituted compounds defined by a structural formula with Ra/Rb as hydrogen or methyl and Z as either fluorine (—F) or radioactive fluorine (—¹⁸F), (ii) pharmaceutical compositions containing the claimed compounds, and (iii) methods of imaging amyloid deposits in a mammal using a detectable quantity of the claimed compound or composition. The estate’s practical value is tied to whether competitors’ amyloid PET tracers land within the same chemical core and whether their chemistry keeps Ra/Rb within hydrogen/methyl and preserves a fluorine/¹⁸F at the Z position.
What compounds does US Patent 8,506,929 claim, and what is the chemical scope?
What is the core claim language that defines coverage?
Independent claim coverage is anchored to “a compound of the formula” with substituent constraints:
- Ra and Rb are independently hydrogen or methyl
- Z is —F or —¹⁸F
This is the key claim architecture: coverage is broad as to the binary choice at two substituent positions (each can be H or Me), but narrow as to (a) the rest of the scaffold implied by the unspecified formula text and (b) only the Z position being fluorinated as either stable F or ¹⁸F.
How many compound variants are explicitly encompassed by the Ra/Rb and Z permutations?
From the claim text you provided, the enumerated substitution combinations are:
- Ra ∈ {H, Me}
- Rb ∈ {H, Me}
- Z ∈ {—F, —¹⁸F}
Total explicit variants = 2 × 2 × 2 = 8 variants under the formula constraint:
- (Ra=H, Rb=H, Z=—F)
- (Ra=H, Rb=H, Z=—¹⁸F)
- (Ra=H, Rb=Me, Z=—F)
- (Ra=H, Rb=Me, Z=—¹⁸F)
- (Ra=Me, Rb=H, Z=—F)
- (Ra=Me, Rb=H, Z=—¹⁸F)
- (Ra=Me, Rb=Me, Z=—F)
- (Ra=Me, Rb=Me, Z=—¹⁸F)
This matters for design-around: competitors can sometimes reduce infringement risk by changing either Ra or Rb to something other than hydrogen/methyl, or by moving fluorine to a different position or using a different label chemistry than the Z position.
Does the claim cover the ¹⁸F-labeled form and the cold ¹⁹F analog?
Yes. Z explicitly includes both —F and —¹⁸F. That indicates coverage spans both the imaging radioisotope and the corresponding non-radioactive fluorinated intermediate/analog, to the extent those compounds fall within the same formula definition.
What is the likely practical meaning of “detectable quantity” in the imaging claims?
In claim 5 and claim 6, the method requires introducing a detectable quantity of the compound/composition and allowing association with amyloid deposits before detecting the associated compound. In enforcement terms, that maps to PET workflows where the labeled tracer accumulates at amyloid plaques and imaging detects the radiolabel signal.
What formulations are protected by US 8,506,929: compositions for amyloid imaging?
What does claim 3 add beyond claim 1?
Claim 3 is a standard composition claim:
- “A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.”
This claim broadens enforcement from compound-only infringement to formulation use, manufacturing, and distribution of a tracer formulation containing one of the claimed compounds plus standard carriers.
What does claim 4 add?
Claim 4 parallels claim 3 for the subject matter of claim 2:
- “A composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier or diluent.”
From the claim text you supplied, claim 2 depends on claim 1, but the exact added constraints in claim 2 are not present in your excerpt. Coverage analysis therefore treats claim 4 as co-extensive with claim 2’s narrower compound definition.
How does “pharmaceutically acceptable carrier or diluent” affect design-around?
Because carrier/diluent is typically functional and not structurally limited, design-around typically cannot be achieved by swapping excipients alone. The main design-around lever remains the tracer chemistry: Ra/Rb and Z.
How do the method claims work: imaging amyloid deposits in a mammal?
What does claim 5 require?
Claim 5 is a method of imaging amyloid deposits in a mammal:
- Introduce into the mammal a detectable quantity of the compound of claim 1
- Allow sufficient time for association with one or more amyloid deposits
- Detect the compound associated with the one or more amyloid deposits
This is a standard PET method format. The claim likely reads on in vivo imaging protocols using the claimed tracer, regardless of the exact machine, provided the detection step involves the radiolabeled compound signal localized to amyloid deposits.
What does claim 6 require?
Claim 6 swaps the input to a composition:
- Introduce detectable quantity of composition of claim 3
- Allow association with amyloid deposits
- Detect associated compound
So claim 6 captures imaging conducted with a formulation rather than dosing the compound as such.
What is the infringement posture likely to be for method claims?
Method claims create two typical infringement surfaces:
- Clinical/hospital imaging protocols (practitioner liability)
- Commercial actors supporting the imaging (depending on the jurisdiction and how inducement or contributory infringement is pursued)
In practice, enforcement usually targets the tracer manufacturer/distributor and the method steps embedded in labeling or instructions for use.
What is the likely patent claim hierarchy within US 8,506,929?
Based on your excerpts:
- Claim 1 is the core chemical claim with Ra/Rb and Z limits.
- Claim 2 depends from claim 1, but the exact narrowing language beyond “compound of claim 1 of the formula” is not included in what you provided.
- Claims 3 and 4 are formulation claims tied to claims 1 and 2, respectively.
- Claims 5 and 6 are method claims tied to claims 1 and 3, respectively.
This hierarchy implies that if claim 1 is found invalid or designed around, dependent claims 3–6 may also fail or be avoided.
How strong is the patent estate for amyloid imaging compounds with —F/—¹⁸F substitution?
What determines intrinsic chemical strength here?
The chemical claim includes explicit substituent constraints:
- Ra and Rb: H or methyl
- Z: —F or —¹⁸F
This creates a clear “all elements” test for infringement. For competitors, validity and enforceability often hinge on whether the scaffold and substitution pattern were novel and non-obvious at the filing date, and whether claim interpretation constrains “formula” sufficiently.
What determines enforceability risk for competitors?
Competitors face three major infringement triggers:
- Their tracer contains the same core scaffold and meets Ra/Rb as H/Me.
- Their labeling places the fluorine/¹⁸F at the Z position defined in the claim formula.
- Their marketing and imaging use aligns with “allowing sufficient time” and “detecting associated with amyloid deposits,” potentially mirrored by clinical protocols.
Because “carrier/diluent” is generic, formulation changes do not necessarily reduce risk if the compound itself is within claim scope.
How do competitors design around Ra/Rb and Z limitations?
Design-around pathway 1: change Ra or Rb to something other than H or methyl
If a competitor substitutes Ra or Rb with ethyl, halogen, hydroxyl, or other groups, it may fall outside claim scope (assuming the rest of the formula scaffold remains intact).
Design-around pathway 2: change the labeling site so Z is not the fluorine/¹⁸F position in claim formula
Switching the ¹⁸F location or switching the radionuclide labeling strategy (for example, using different isotopes or non-fluorinated detection handles) can defeat the Z element.
Design-around pathway 3: use a non-amyloid target or a fundamentally different detection mechanism
Avoiding “amyloid deposits” as the target, or using a different class of amyloid binding agents outside the claimed compounds, can defeat method claim elements. But that is a program-level change, not a small formulation tweak.
What patent landscape questions matter for US 8,506,929: which claims drive licensing and litigation?
What claims drive the strongest settlement leverage?
For a tracer program, the highest leverage typically comes from:
- Claim 1 (compound coverage)
- Claim 5 (in vivo imaging method coverage)
- Claim 3/6 (composition and method using the composition)
If a party can avoid claim 1 by chemistry design, method claims may still be contested depending on whether their use still involves a claimed compound.
What litigation posture usually follows for this claim style?
For PET tracers, disputes usually cluster around:
- Claim construction of the “formula” boundaries and the meaning of substituent positions
- Whether the accused tracer meets Ra/Rb and Z constraints
- Whether imaging protocols match the method steps and whether the accused product is “detectable quantity” and “associated with amyloid deposits”
What is the US regulatory and market exclusivity context for amyloid PET tracers?
The patent you supplied is a US utility patent. In the United States, market exclusivity and IP interactions typically involve:
- FDA approval and labeling (which can affect method claim infringement narratives)
- Patent listings in the Orange Book for approved drugs where applicable
- Radioactive imaging products often have specialized regulatory pathways, but patent strategy still hinges on whether competitors can launch generics or “radiopharmaceutical equivalents” while using a modified tracer chemistry
No Orange Book entry details are provided in your prompt, so the analysis here remains at the level of claim architecture and likely enforcement surfaces.
Which product types are most exposed to US 8,506,929 risk?
Most exposed
- ¹⁸F-labeled amyloid PET tracers that match the claimed compound formula
- Finished radiotracer formulations that deliver one of the claimed compounds with standard carriers
- Any imaging kit or instructions that align with the claimed administration and detection method using the claimed compound
Lower exposure
- Tracers that retain amyloid-binding activity but alter Ra/Rb or move fluorine off the Z position defined in claim formula
- Non-fluorinated tracers
- Compounds that use different labeling approaches not captured by “Z is —F or —¹⁸F” at the specified structural locus
Key Takeaways
- US 8,506,929 covers an amyloid imaging tracer family defined by a formula with tight substituent limits: Ra/Rb are H or methyl and Z is —F or —¹⁸F.
- The estate supports three enforcement layers: compound (claim 1), formulation (claim 3/4), and in vivo imaging methods (claim 5/6).
- Design-around typically depends on changing either Ra or Rb away from H/Me, or relocating/changing the labeling so the Z position is not fluorine/¹⁸F as claimed.
- Method claims increase exposure for clinical and commercial actors executing dosing and imaging workflows consistent with amyloid plaque localization.
FAQs
1) Does US 8,506,929 cover both cold fluorine (—F) and PET fluorine (—¹⁸F)?
Yes. The claim defines Z as —F or —¹⁸F, so both the non-radioactive analog and the PET-labeled tracer fall within the formula limits.
2) Can a competitor avoid infringement by changing only the carrier or excipient?
Not if the delivered tracer compound still meets the claim 1 formula constraints. Claims 3 and 4 cover compositions using standard pharmaceutically acceptable carriers and do not narrow coverage based on excipient identity.
3) What is the most direct chemistry-based design-around lever?
Changing Ra and/or Rb from hydrogen or methyl, or altering the structure so the labeling position corresponding to Z is not —F/—¹⁸F as claimed.
4) Do the method claims require a specific imaging technology?
The method requires introducing detectable quantity, waiting for association with amyloid deposits, and detecting the compound associated with deposits. The claim text you provided does not restrict the scanner technology.
5) Is the imaging method claim broader or narrower than the compound claim?
It is narrower in that it requires specific in vivo steps and the amyloid imaging context, but it can still be strategically important because it targets real-world use of the tracer compound or composition.
References (APA)
- United States Patent. US 8,506,929. (Claim text provided by user).
